UNSPSC 51271802: Hexylcaine

This classification denotes an anesthetic agent with the molecular formula C16H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 511IU0826Z, chemically known as 2-propanol, 1-(cyclohexylamino)-, benzoate (ester) but generally known as hexylcaine, which bears US NIH Compound Identifier 10770. European Medicines Agency schedules Hexylcaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08043MIG.

UNSPSC 51271802 Hexylcaine, a Commodity code, encompasses local anesthetic pharmaceuticals that state and local governments procure through cooperative purchasing agreements and multi-source generic drug programs. Recent activity shows state and local health systems sourcing hexylcaine and similar injectable anesthetics as components of broader pharmaceutical supply contracts rather than as standalone line items. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body active under this code, leveraging cooperative purchasing vehicles to aggregate demand across multiple participating jurisdictions and states. MMCAP coordinates procurement on behalf of state agencies, counties, municipalities, and other government facilities across member states including Minnesota and Oregon. Health systems and government pharmacies drive demand through these cooperative agreements, which require vendors to maintain relationships with authorized pharmaceutical wholesalers and comply with cGMP and Drug Supply Chain Security Act requirements.

MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products (solicitation S1070000015802, due March 26, 2026) illustrates the current market. The cooperative seeks manufacturers capable of supplying hexylcaine and related pharmaceutical products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with pricing evaluated at 75 percent weight and administrative and operational compliance (EDI capability, cGMP certification, DSCSA compliance) at 25 percent combined. Vendors must submit detailed product information including National Drug Codes, SKUs, UPCs, and manufacturing locations, maintain $5 million commercial general liability insurance and $2 million network security liability coverage, and accept a 3 percent administrative fee on all purchases. The contract term runs two years for new vendors with optional extensions, with awards effective July 1, 2026. No specific set-aside designations were identified in the RFP documentation.